Literature DB >> 12933403

Defining neuropathic pain.

Misha-Miroslav Backonja1.   

Abstract

Clinical research and practice have suffered because of lack of specificity when clinical diagnoses of pain are made. Distinction between neuropathic and inflammatory pain mechanisms is suggested, as well as the distinction between neuropathic pain from hypersensitivity pain disorders, previously termed neuropathic pain due to neurological dysfunction. Neuropathic pain is in this case defined as pain occurring in the ara of body affected by neurological disease or injury. This type of pain manifests not only with positive sensory phenomena such as pain, dysesthesia, and different types of hyperalgesia, but also with negative sensory phenomena and negative and positive motor and autonomic symptoms and signs.

Entities:  

Mesh:

Year:  2003        PMID: 12933403     DOI: 10.1213/01.ane.0000062826.70846.8d

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  36 in total

1.  The 2010 Annual Conference of the Canadian Pain Society.

Authors: 
Journal:  Pain Res Manag       Date:  2010 Mar-Apr       Impact factor: 3.037

2.  Reliability and validity of the Japanese translation of the DN4 Diagnostic Questionnaire in patients with neuropathic pain.

Authors:  Yuka Matsuki; Norihiko Sukenaga; Ken Miyagi; Takashi Tsunetoh; Maki Mizogami; Kenji Shigemi; Lynn Maeda; Munetaka Hirose
Journal:  J Anesth       Date:  2018-05-05       Impact factor: 2.078

3.  Critical role of microglial CD40 in the maintenance of mechanical hypersensitivity in a murine model of neuropathic pain.

Authors:  Ling Cao; Christopher D Palmer; Jennifer T Malon; Joyce A De Leo
Journal:  Eur J Immunol       Date:  2009-12       Impact factor: 5.532

4.  TREK2 expressed selectively in IB4-binding C-fiber nociceptors hyperpolarizes their membrane potentials and limits spontaneous pain.

Authors:  Cristian Acosta; Laiche Djouhri; Roger Watkins; Carol Berry; Kirsty Bromage; Sally N Lawson
Journal:  J Neurosci       Date:  2014-01-22       Impact factor: 6.167

Review 5.  Nicotinic ACh receptors as therapeutic targets in CNS disorders.

Authors:  Kelly T Dineley; Anshul A Pandya; Jerrel L Yakel
Journal:  Trends Pharmacol Sci       Date:  2015-01-29       Impact factor: 14.819

6.  Descending facilitation maintains long-term spontaneous neuropathic pain.

Authors:  Ruizhong Wang; Tamara King; Milena De Felice; Wenhong Guo; Michael H Ossipov; Frank Porreca
Journal:  J Pain       Date:  2013-04-19       Impact factor: 5.820

7.  Ultrasmall Superparamagnetic Iron Oxide Imaging Identifies Tissue and Nerve Inflammation in Pain Conditions.

Authors:  Shiqian Shen; Weihua Ding; Shihab Ahmed; Ranliang Hu; Arissa Opalacz; Sarah Roth; Zerong You; Gregory R Wotjkiewicz; Grewo Lim; Lucy Chen; Jianren Mao; John W Chen; Yi Zhang
Journal:  Pain Med       Date:  2018-04-01       Impact factor: 3.750

Review 8.  Measuring GABAergic inhibitory activity with TMS-EEG and its potential clinical application for chronic pain.

Authors:  Mera S Barr; Faranak Farzan; Karen D Davis; Paul B Fitzgerald; Zafiris J Daskalakis
Journal:  J Neuroimmune Pharmacol       Date:  2012-06-29       Impact factor: 4.147

9.  Analyses of long non-coding RNA and mRNA profiles in the spinal cord of rats using RNA sequencing during the progression of neuropathic pain in an SNI model.

Authors:  Jun Zhou; Youling Fan; Hongtao Chen
Journal:  RNA Biol       Date:  2017-09-29       Impact factor: 4.652

Review 10.  Neuromodulating drugs for the symptomatic treatment of neuropathic pain.

Authors:  Miroslav Backonja
Journal:  Curr Pain Headache Rep       Date:  2004-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.